Dr. Timos Papagatsias’ Post

Thoughts on this? >> GoodRx: Evolving & Expanding Integrated Platform Partnerships to Drive Access, Affordability & Outcomes >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #biotech #productmarketing

GoodRx: Evolving & Expanding Integrated Platform Partnerships to Drive Access, Affordability & Outcomes: Today’s guest post comes from Rick Fry, VP of Strategic Development at GoodRx. Rick explains why patients and pharmaceutical manufacturers now pay a greater share of prescription costs. He outlines GoodRx's services that address the twin challenges when the patient is the payer and the manufacturer faces intense gross-to-net pressures. To learn more, download the GoodRx case study: GoodRx Integrated Platform Solutions: Patient Navigator + Integrated Copay Card. Read on for Rick’s insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only. #pbm #lifesciences #financial

GoodRx: Evolving & Expanding Integrated Platform Partnerships to Drive Access, Affordability & Outcomes: Today’s guest post comes from Rick Fry, VP of Strategic Development at GoodRx. Rick explains why patients and pharmaceutical manufacturers now pay a greater share of prescription costs. He outlines GoodRx's services that address the twin challenges when the patient is the payer and the manufacturer faces intense gross-to-net pressures. To learn more, download the GoodRx case study: GoodRx Integrated Platform Solutions: Patient Navigator + Integrated Copay Card. Read on for Rick’s insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only. #pbm #lifesciences #financial

Thoughts on this? >> Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #productmarketing #pharma

Thoughts on this? >> Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #healthcare #pharma

Thoughts on this? >> Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #productmarketing

Thoughts on this? >> Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #biotech #healthcare

Expanding our Definitions of Out-of-Pocket Costs: Three Imperatives for Biopharmaceutical Manufacturers: Today’s guest post comes from Christine Juday, Head of Market Access at Real Chemistry. Chris discusses new research on how patients perceive out-of-pocket costs. As she explains, many patients and unpaid caregivers consider out-of-pocket costs for medication within the context of their total spending. She then recommends three ways that manufacturers can improve patients' access and affordability. Click here to learn more about Real Chemistry’s suite of market access consulting and payer/IDN marketing solutions. You can also sign up for its weekly Value Report, summarizing the week in drug pricing, access, and value news. Read on for Chris' insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only. #pbm #lifesciences #financial

🔍 A recent study in Health Affairs highlights how hospitals' drug price markups are not only incentivizing consolidation within the healthcare industry but are also adversely affecting funding for pharmaceutical innovation. This consolidation trend could lead to less competition and higher prices for patients, emphasizing the need for policy reforms to ensure fair pricing and support innovation. Read the article here: https://lnkd.in/dRStN4YQ

Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations: Once relatively obscure, PBMs are now front and center in debates over drug pricing and access. Their future role will have profound implications not only for how medications are priced but also for how pharmacies conduct their operations. #finance #pharmacy #lifesciences